COVID-19 Vaccine: Chadox1 by Oxford University shows some positive results in monkeys, human trails still underway
HealtScientists all over the world are racing to launch a vaccine for the new coronavirus. As per the World Health Organization, eight vaccine candidates in the world are already in the human trial phase and 110 more are right now in preclinical stages.
The Oxford University’s Chadox1 entered human trials late April. The vaccine is an adenovirus vector that reportedly develops a strong immune response with only one shot. Now, a preprint research article released by the university says that the vaccine is effective in rhesus monkeys who received a shot of the vaccine before the human trials began.
The study is not peer-reviewed yet but has been shared online to help public health experts learn more about COVID-19.
For the study, Dr Sarah Gilbert, one of the lead scientists in the Chadox1 team, and her colleagues injected their adenovirus vaccine in six rhesus macaques, a non-human primate that is often used in biomedical research. The dose of the vaccine was half that of what is being used for humans right now.
Three other monkeys were kept as controls and were given Chadox GFPs - a control vaccine which does not create an immune response but has a green fluorescent protein to study it - in the same dose as is being given to humans right now.
The team found that a single dose of the vaccine stimulated both the arms - cell-mediated and humoral - of the adaptive immunity (the one you develop after being infected with a microbe). Antibodies against the targetted spike protein of the virus were found in all the 6 monkeys within 14 days of immunisation, whereas no antibodies against the COVID-19 causing virus were found in the control group.
Upon being injected with the virus, all the monkeys showed a significant reduction in viral load (amount of virus present) in their respiratory tract and did not develop signs of pneumonia.
Also, none of the infected animals showed signs of severe or worse disease on being injected with the virus.
Chadox1 is an adenovirus vector-based vaccine being developed at the Jenner Institute under the Oxford University.
Adenovirus vectors are the most common type of vectors used for vaccine development. Vector vaccines involve the use of other live or dead microbes to pass on the DNA/RNA (nucleic acid) of the target microbe into the body of a person. When you get the vaccine, your immune system reacts to it in the same way it would if you were exposed to the target microbe in a natural setting and produce antibodies against the said microbe. Hence, without ever getting sick you will be protected from the disease.
The vaccine uses the DNA sequence for the spike protein from SARS-CoV-2, the causative agent of COVID-19. The adenovirus vector in Chadox1 will not replicate inside the human body, which is why it is being considered safe for the elderly and children too.
For more information, read our article on Why is it taking so long to develop a vaccine for COVID-19?
Health articles in Firstpost are written by myUpchar.com, India’s first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.
Updated Date: May 19, 2020 13:16:29 IST
Tags : chadox1, Coronavirus, Coronavirus India, Coronavirus News, Coronavirus Outbreak, Coronavirus Pandemic, COVID-19, covid19, Health India Positive, Myupchar, NewsTracker, Novel Coronavirus, Oxford University, Vaccine, WHO
The information provided here is intended to provide free education about certain medical conditions and certain possible treatment. It is not a substitute for examination, diagnosis, treatment, and medical care provided by a licensed and qualified health professional. If you believe you, your child or someone you know suffers from the conditions described herein, please see your health care provider immediately. Do not attempt to treat yourself, your child, or anyone else without proper medical supervision. You acknowledge and agree that neither myUpchar nor firstpost is liable for any loss or damage which may be incurred by you as a result of the information provided here, or as a result of any reliance placed by you on the completeness, accuracy or existence of any information provided herein.
Why social distancing is still the most effective non-pharmaceutical intervention for COVID-19
Studies suggest even mild symptoms of COVID-19 can cause severe damage to lungs, heart and brain
COVID-19 Treatment: Bemcentinib, Heparin and 3 other drugs to be tested by UK in their ACCORD programme
Hydroxychloroquine sustained dose and PPE can reduce COVID-19 risk in healthcare workers, ICMR study says
COVID-19 Testing: Gold nanoparticle-based test kit can give results within 10 minutes
New French study suggests 10% of diabetes patients who contract COVID-19 die within a week
Coronavirus Outbreak Updates: 2,091 people test positive for COVID-19 in Maharashtra today; confirmed cases rise to 54,758 in state
Coronavirus Outbreak Updates: 459 people test positive for COVID-19 in Pune today, total number of cases rises to 6,153
Coronavirus Outbreak Updates: Gujarat BJP MLA Balram Thawani tests positive for COVID-19; 423 new cases reported in state today
Coronavirus Outbreak Updates: Mumbai reports 1,382 new COVID-19 cases; confirmed infections rise to 25,317
Coronavirus Outbreak Updates: Junior assistant in Delhi LG's office tests positive for COVID-19; samples from 40 staff members taken
Coronavirus Outbreak Updates: Film producers' association writes to Uddhav Thackeray requesting resumption of film and TV shoots